No significant diurnal rhythmicity of short chain fatty acids in the blood was observed. by Weiran Shan (16969688)

The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. by Shobnom Mustaree (21728815)

Distribution of population at final time (left) and change in mean MSI at final time (right) from simulations across 1000 parameter sets when weevils are absent (red) and with weev... by Alexandra M. Campbell (3284094)

Subjects:

Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

Table 1_Multi-generational adaptation to Solanum nigrum increases reproduction and decreases microbial diversity of Aphis gossypii.docx by Peng Wang (34436)

“…The relative abundance of Buchnera in T5 and T10 significantly increased compared to M and T, while the relative abundance of Arsenophonus decreased markedly. …”

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects: